Metabolite News and Research

RSS

Metabolites are the intermediates and products of metabolism. The term ''metabolite'' is usually restricted to small molecules.

Harbor BioSciences to receive patent for Apoptone in treatment of prostate cancer, breast cancer and benign prostatic hypertrophy

Harbor BioSciences, Inc. today announced that the company has received a notice of allowance from the United States Patent Office of patent claims covering the use of its lead product candidate Apoptone®. The patent claims cover the use of Apoptone to treat prostate cancer, breast cancer and benign prostatic hypertrophy. Apoptone (HE3235) is a novel synthetic steroid analog of a dihydrotestosterone metabolite and has been found to stimulate cell death (apoptosis) in animal models of prostate and breast cancers.

25 Feb 2010

Enzon Pharmaceuticals initiates treatment in PEG-SN38 Phase 1 study for pediatric cancer patients

Enzon Pharmaceuticals, Inc. today announced that the first patient has been treated in the Phase 1 study of PEG-SN38 for pediatric cancer patients. PEG-SN38 or EZN-2208 is Enzon’s PEGylated form of SN38, the active metabolite of the cancer drug Camptosar® (irinotecan HCl injection). The study is designed to find the recommended dose of PEG-SN38 in pediatric patients. The PEG-SN38 compound is currently being evaluated in Phase 2 studies for metastatic colorectal and breast cancer.

24 Feb 2010

Chiltern International and Charles River Laboratories to study radiolabelled drug products

Chiltern International Limited, a global contract research organization (CRO), announced its latest collaboration with Charles River Laboratories, Inc. As part of this collaboration, Chiltern Early Phase will partner with Charles River to conduct and support early phase radiolabelled studies.

22 Feb 2010

Researchers identify specific metabolic profiles that predict risk of heart attack and death

Tiny bits of molecular "trash" found in circulating blood appear to be good predictors of cardiovascular disease and untimely death, say researchers at Duke University Medical Center.

19 Feb 2010

Unusual compounds in pitcher plant could prove effective against human fungal infections

The moment insects like flies, ants and beetles fall into a pitcher, the plant's enzymes are activated and begin dissolving their new meal, obtaining nutrients such as carbon and nitrogen which are difficult to extract from certain soils.

19 Feb 2010

Researchers find gene mutations that may provide clues for treating AML patients

Although leukemia is one of the best studied cancers, the cause of some types is still poorly understood. Now, a newly found mutation in acute myeloid leukemia patients could account for half of the remaining cases of adult acute leukemia with an unknown origin.

19 Feb 2010

Protein crucial in mediating anti-inflammatory actions of nuclear lipid receptors discovered

Researchers at the Swedish medical university Karolinska Institutet have discovered a protein that is crucial in mediating the anti-inflammatory actions of nuclear lipid receptors. The findings, published in the research journal Genes & Development, link lipid metabolism and inflammation and open up new possibilities for developing treatments of metabolic diseases associated with inflammation, such as diabetes and atherosclerosis.

17 Feb 2010

RI-MUHC and McGill University teams receive $5M CIHR grant for environmental and reproductive health studies

Two teams from the Research Institute of the McGill University Health Centre (RI-MUHC) and McGill University received significant support from the Canadian Institutes of Health Research (CIHR) amounting to $5 million over five years.

15 Feb 2010

New project to unravel secret lives of cancer cells may help produce new cancer therapies

A team of scientists from Princeton University and The Cancer Institute of New Jersey has embarked on a major new project to unravel the secret lives of cancer cells that go dormant and self-cannibalize to survive periods of stress. The work may help produce new cancer therapies to stem changes that render cancer cells dangerous and resistant to treatment.

12 Feb 2010

PAREXEL International, Proteome Sciences form biomarker alliance

PAREXEL International Corporation, a leading global biopharmaceutical services provider, and Proteome Sciences plc, a leading provider of protein biomarker discovery, validation, and assay development services, today announced the formation of an alliance focused on enhancing PAREXEL's biomarker capabilities for early phase clinical development. PAREXEL is using Proteome Sciences' PS Biomarker Services™ protein and peptide biomarker capabilities to support biopharmaceutical companies in making earlier assessments of new compounds in development.

From Parexel 11 Feb 2010

QR Pharma commences clinical trial of Posiphen in early stage AD patients

QR Pharma, Inc. , a developer of novel drugs to treat Alzheimer’s disease, announced today that it began a clinical trial of its lead compound, Posiphen, in early stage AD patients.

10 Feb 2010

Concomitant use of dexlansoprazole and other PPIs with Plavix: TGRD U.S. initiates trial

Takeda Global Research & Development Center, Inc., U.S., (TGRD U.S.) announced today that it has initiated a trial to study how dexlansoprazole and several other proton pump inhibitors (PPIs) affect the pharmacokinetics and pharmacodynamics of Plavix (clopidogrel bisulfate) in healthy subjects. Takeda has been evaluating all published data and communications from the U.S. Food and Drug Administration (FDA) regarding the potential risks associated with concomitant use of clopidogrel and PPIs.

10 Feb 2010

Breast cancer patients taking antidepressant paroxetine at the same time as tamoxifen are at increased risk of death

Women with breast cancer who take the antidepressant paroxetine at the same time as tamoxifen are at an increased risk of death, concludes a study published on bmj.com today.

10 Feb 2010

Scientists identify enzyme mutations in AML patients

A study published online on February 8 in the Journal of Experimental Medicine (www.jem.org) reports that several distinct mutations found in a subset of patients with acute myelogenous leukemia (AML) result in excess production of the same metabolite.

9 Feb 2010

Phthalate exposure can affect child's neurobehavioral development, says study

A new study led by Mount Sinai researchers in collaboration with scientists from Cornell University and the U.S. Centers for Disease Control and Prevention, has found higher prenatal exposure to phthalates-manmade chemicals that interfere with hormonal messaging-to be connected with disruptive and problem behaviors in children between the ages of 4 and 9 years.

28 Jan 2010

Researchers identify treatment to reduce health problems associated with enzyme defect

An experimental compound repaired a defective alcohol metabolism enzyme that affects an estimated 1 billion people worldwide, according to research supported by the National Institute on Alcohol Abuse and Alcoholism (NIAAA).

10 Jan 2010

Nutrient mix shows potential to improve memory in Alzheimer's patients

In the early stages of Alzheimer's disease, patients typically suffer a major loss of the brain connections necessary for memory and information processing. Now, a combination of nutrients that was developed at MIT has shown the potential to improve memory in Alzheimer's patients by stimulating growth of new brain connections.

7 Jan 2010

Enzon Pharmaceuticals treats first patient in Phase 2 studies of PEG-SN38

Enzon Pharmaceuticals, Inc. today announced that the first patient has been treated in the Phase 2 studies of PEG-SN38 for metastatic breast cancer. PEG-SN38 or EZN-2208 is Enzon’s PEGylated form of SN38, the active metabolite of the cancer drug Camptosar® (irinotecan HCl injection).

6 Jan 2010

Anti-aromatase phytochemicals in pomegranates reduce hormone-dependent breast cancer

Eating fruit, such as pomegranates, that contain anti-aromatase phytochemicals reduces the incidence of hormone-dependent breast cancer, according to results of a study published in the January issue of Cancer Prevention Research, a journal of the American Association for Cancer Research.

5 Jan 2010

University of Western Ontario receives grant to conduct randomized trial for Crohn's disease

Robarts Clinical Trials at The University of Western Ontario in London, Canada, has been awarded a 4.7 million dollar grant to conduct a randomized controlled trial evaluating treatment options for Crohn's disease.

5 Jan 2010

Metabolite News and Research

Further Reading

Harbor BioSciences to receive patent for Apoptone in treatment of prostate cancer, breast cancer and benign prostatic hypertrophy

Enzon Pharmaceuticals initiates treatment in PEG-SN38 Phase 1 study for pediatric cancer patients

Chiltern International and Charles River Laboratories to study radiolabelled drug products

Researchers identify specific metabolic profiles that predict risk of heart attack and death

Unusual compounds in pitcher plant could prove effective against human fungal infections

Researchers find gene mutations that may provide clues for treating AML patients

Protein crucial in mediating anti-inflammatory actions of nuclear lipid receptors discovered

RI-MUHC and McGill University teams receive $5M CIHR grant for environmental and reproductive health studies

New project to unravel secret lives of cancer cells may help produce new cancer therapies

PAREXEL International, Proteome Sciences form biomarker alliance

QR Pharma commences clinical trial of Posiphen in early stage AD patients

Concomitant use of dexlansoprazole and other PPIs with Plavix: TGRD U.S. initiates trial

Breast cancer patients taking antidepressant paroxetine at the same time as tamoxifen are at increased risk of death

Scientists identify enzyme mutations in AML patients

Phthalate exposure can affect child's neurobehavioral development, says study

Researchers identify treatment to reduce health problems associated with enzyme defect

Nutrient mix shows potential to improve memory in Alzheimer's patients

Enzon Pharmaceuticals treats first patient in Phase 2 studies of PEG-SN38

Anti-aromatase phytochemicals in pomegranates reduce hormone-dependent breast cancer

University of Western Ontario receives grant to conduct randomized trial for Crohn's disease

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News